AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Solid Tumors|Lymphoma|Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer
Interventions: DRUG: AZD5153|DRUG: Olaparib
Sponsor: AstraZeneca